You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

chimeric receptor

Showing 26 - 50 of 7,774
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Serum Neurofilament Light asMarker for Brain Injury in

Recruiting
  • Neurotoxicity
    • Saint Louis, Missouri
      Washington University School of Medicine
    Oct 10, 2022

    Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)

    Not yet recruiting
    • Gastric Cancer
    • +3 more
    • LB1908
    • (no location specified)
    Sep 9, 2022

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

    Not yet recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • +5 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2023

    Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

    Active, not recruiting
    • Sarcoma
    • Autologous HER2-specific T cells
    • +3 more
    • Houston, Texas
    • +1 more
    Nov 21, 2022

    SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

    Not yet recruiting
    • SLE (Systemic Lupus)
    • CAR T-cell therapy
    • Bangkok, Please Select, Thailand
      King Chulalongkorn Memorial Hospital
    Nov 23, 2023

    Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

    Completed
    • Sarcoma
    • +3 more
    • Anti-GD2-CAR engineered T cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 31, 2023

    Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

    Not yet recruiting
    • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
    • Zhengzhou, Henan, China
      Henan cancer hospital
    Nov 28, 2022

    Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

    Not yet recruiting
    • Chronic Graft Versus Host Disease
    • +2 more
    • Biopsy
    • +11 more
    • Duarte, California
      City of Hope Medical Center
    Aug 7, 2023

    Blood Cancer Trial (KCAT19 T cells)

    Not yet recruiting
    • Blood Cancer
    • KCAT19 T cells
    • (no location specified)
    May 20, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • São Paulo, Brazil
      Hospital Israelita Albert Einstein
    Jan 20, 2023

    Non Hodgkin Lymphoma Trial in San Francisco (Neuropsychological testing)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • Neuropsychological testing
    • San Francisco, California
      Stanford Cancer Center
    Nov 9, 2022

    Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia Trial in Saint Louis (Duvelisib)

    Recruiting
    • Non-hodgkin Lymphoma
    • Acute Lymphocytic Leukemia
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jun 30, 2022

    Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

    Recruiting
    • Advanced Solid Tumors
    • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
    • Hangzhou, China
      First affiliated hospital, School of Medicine, Zhejiang Universi
    Aug 3, 2023

    Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma Trial in Nashville (Telemedicine Visit, Vital sign measurements,

    Recruiting
    • Large B-cell Lymphoma
    • Diffuse Large B-cell Lymphoma
    • Telemedicine Visit
    • +3 more
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    Sep 28, 2022

    Metastatic Castration-resistant Prostate Cancer Trial (TmPSMA-02)

    Not yet recruiting
    • Metastatic Castration-resistant Prostate Cancer
    • TmPSMA-02
    • (no location specified)
    Aug 3, 2022

    Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19

    Recruiting
    • Lymphoblastic Leukemia
    • +5 more
    • Anti-CD19 CAR T-cells
    • Singapore, Singapore
    • +1 more
    Dec 4, 2022

    Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

    Active, not recruiting
    • Multiple Myeloma
    • Infusion of MCARH109 T cells
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jul 5, 2022

    Lymphoma, Leukemia, Myeloma Trial in Tampa (Resistance Training, Aerobic Exercise)

    Recruiting
    • Lymphoma
    • +2 more
    • Resistance Training
    • Aerobic Exercise
    • Tampa, Florida
      Moffitt Cancer Center
    Feb 28, 2023

    Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

    Recruiting
    • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 3, 2022

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

    Not yet recruiting
    • Lymphoid Leukemia
    • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
    • Treg CD34+ HSPC (Orca-T)
    • Palo Alto, California
      Stanford Cancer Center
    Aug 17, 2022

    Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • chimeric antigen receptor T cell
    • Beijing, Beijing, China
      Beijing Boren Hospital
    Aug 12, 2022

    Brain and Nervous System Trial in Palo Alto (B7-H3CART)

    Recruiting
    • Brain and Nervous System
    • Palo Alto, California
      Stanford Cancer Institute
    Jul 22, 2022